Addictions are psychiatric disorders that are associated with maladaptive and destructive behaviours, and that have in common the persistent, compulsive and uncontrolled use of a drug or an activity. Addictive agents induce adaptive changes in brain function; these changes are the bases for tolerance and for the establishment of craving, withdrawal and AFFECTIVE DISTURBANCE, which persist long after consumption ceases 1 . This self-maintaining and progressive neurobiology of addictions makes them chronic and relapsing disorders.
The addictions are a worldwide public-health crisis, and exert corrosive effects at family and societal levels, leading even to the narco-political and narco-economic domination of countries and regions. The World Health Organization (WHO) estimated that there are 2 billion alcohol users, 1.3 billion tobacco users, and 185 million users of illicit drugs (see the WHO reports in the Online links box). In 2001, these three categories together contributed to 12.4% of deaths worldwide (see the WHO reports in the Online links box). According to the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) 2 , the one-year POINT PREVALENCE of DSM-IV (the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders issued by the American Psychiatric Association) substance-use disorders (excluding nicotine) is 9.35% in the United States, representing 19.4 million adults BOX 1. As well as causing ~590,000 deaths per year in the United States, addictive drugs also cause injury or illness to almost 40 million individuals 3 . On a population basis, alcoholism alone subtracts an average of 4.2 DISABILITY ADJUSTED LIFE YEARS (DALYs) per person, tobacco subtracts 4.1 DALYs and illicit drugs subtract 0.8 DALYs. For comparison, AIDS subtracts 6.0 DALYs and type 1 diabetes subtracts 0.1 DALYs 4 . The addiction disease burden is unequally distributed across countries; drugs have a higher impact in the United States and Europe than in developing countries where life expectancies are shorter (see the WHO reports in the Online links box).
Environmental and genetic factors contribute to individual differences in vulnerability to initiating use of addictive agents and in vulnerability to the shift from use to addiction. Cross-sectional studies on large twin samples also indicate that a mixture of environmental and genetic influences are shared between diseases 5 and provide a link between the normal range of behavioural variation and PSYCHOPATHOLOGY 6, 7 . However, because addictions are in theory entirely preventable by law or individual choice, it has been argued that addictions are a low priority for genomic research 4 . Substance use shapes patterns of abuse and dependence, and conversely, addictive drugs are largely consumed by C a n n a b is S t im u la n t s C o c a in e A n x io ly t ic s O p ia t e s
P s y c h e d e li c s
In h a la n t s addicted individuals 8 . Addictive substances are widely used worldwide 9 (FIG. 1) . However, voluntary or enforced choice has met with partial success. Restrictions generally reduce addictions but are variably applied. Furthermore, the addictions encompass non-substance related behaviours that are widespread and that might access the same neurobiological pathways that modulate reward 10 , impulsive and compulsive behaviour, and mood. These diverse behaviours, including binge eating, compulsive gambling and playing video games, resemble the substance addictions in their clinical course and harmful effect. Therefore, the public-health impact of gene discovery for the addictions is potentially very large, as Merikangas and Risch 4 noted. The origins of addiction vulnerability are complex and wide-ranging; the underlying genetic factors need to be identified to solve the puzzle of what causes these pervasive and relatively intractable disorders. Fortunately, the establishment of widely accepted definitions has created a unifying framework for research and for the clinical treatment of disorders that frequently share neurobiological and clinical course 11 BOXES 1, 2. In this review, we describe our current understanding of addictions. We begin by comparing their mode of inheritance and then discuss the nature of inherited factors, including the genetic risk factors that are shared across diseases versus disease-specific factors, and evidence for POLYGENICITY and HETEROGENEITY. We describe the progress that has been made in gene mapping, including recent work that has used intermediate phenotypes as predictors of vulnerability, and studies of candidate addiction-predisposing genes in animal models. We conclude by discussing the integration of genotypes into diagnosis; this goal is particularly timely given the enormous public-health impact of addictions and the potential power of precisely and inexpensively defined genotypes associated with these heritable diseases.
Inheritance of addictions
The inheritance of addictions has been evaluated in many ways, including studies on families and adoptees, but the cornerstone of our knowledge comes from the patterns of correlations in monozygotic (MZ) and dizygotic (DZ) twins.
Addictions are among the most heritable of psychiatric disorders, as shown in studies of large, carefully characterized cohorts of twins TABLE 1, including epidemiologically ascertained cohorts from Virginia, USA, and Australia. HERITABILITIES range from 0.39 (for hallucinogens) to 0.72 (for cocaine) (FIG. 2a) . These moderate to high heritabilities are seemingly paradoxical: addiction depends initially on individual choice to use an addictive agent (so, if a person chooses to use a drug, how can addiction to the drug be heritable?) and wide variations in ADDICTION LIABILITY are observed across time and space. However, heritability studies are generally carried out within populations and age-cohorts that share a substantial likelihood of exposure. Furthermore, it is becoming clear that susceptibility to several complex diseases -coronary artery disease, obesity, cancer and AIDS -is genetically influenced, but also depends profoundly on lifestyle choices. It should also be emphasized that, within populations, exposures are frequently pervasive (for example, exposure to nicotine, alcohol, gambling and caffeine in the United States) and that twin studies therefore cannot expose the full range of genotypes that underlie addiction. In addition, certain individuals are predisposed to initiate use. Heritabilities for initiation and use are generally lower than for dependence, but are still significant 12, 13 . Finally, heritabilities should not be overinterpreted as absolute levels of genetic influence. Heritabilities are estimates that are based on correlations, and are subject to sampling and methodological errors, so the accuracy of diagnosis or the measurement error places a limit on the strength of correlations. Because the total variance includes measurement error and gene-environment covariance, the role of unshared environmental factors cannot be calculated by subtracting heritable variance in liability from total variance. Addiction liability and heritability. Drugs differ in their addiction liability. Addictive liability should correlate with heritability of addiction if variation in the neurobiological basis of addiction is what is being inherited. Although addiction liability is difficult to quantify, Goldstein and Kalant ranked relative risks of addiction to different classes of substances 14 . Using those risk rankings as crude indicators, it seems that addiction liability predicts heritability moderately well, as shown in FIG. 2b . Cocaine and opiates, among the most addictive of substances, are among the most heritable. On the other hand, hallucinogens are among the least addictive, and are also the least heritable. These data seem to point towards an inheritance of variation in the core neurobiological basis of addiction, such as the pathways that mediate reward, behavioural control, obsessionality, compulsivity, or stress and anxiety response. If genes that underlie such variation are detected, they might be informative across addiction disorders and for other behavioural differences that are determined by the same neurobiological processes.
Mode of inheritance. The addictions are inherited as common, complex diseases that show no obvious pattern of Mendelian transmission 15 . However, beyond the importance of environmental interactions, the origin of the complexity is poorly understood. It is tempting to imagine that addictions are polygenic, with vulnerability arising from the simultaneous impact of functional variations at several genes. This model of composite, vulnerable neurobiological processes is consistent with the variety of pathways involved, and the numerous genes involved in these pathways, any one of which could have functional genetic variants. Under a polygenic model, the simultaneous inheritance of many genetic variants (shown as a combination of puzzle pieces in FIG. 3a) is necessary for expression of the disease. However, the molecular complexity of the neural systems can also lead to genetic heterogeneity: a single genetic variation determines vulnerability and RESILIENCY, but different variants (FIG. 3a) can suffice for expression of the disease in different individuals and families. Polygenicity and heterogeneity have a different effect on MZ:DZ twin concordance ratios (FIG. 3b) . These ratios can thereby provide a test to investigate whether a disease is polygenic. This is because MZ twins share all alleles but DZ twins are unlikely to share a combination of alleles. Certain psychiatric diseases (for example, autism and schizophrenia) have high or moderately high MZ:DZ ratios, indicating they might be polygenic or at least oligogenic. The MZ:DZ twin concordance ratios (FIG. 4) reveal no powerful imprint of polygenicity on the inheritance of most addictions, although modest polygenic effects are sometimes seen. For example, the ratio for cocaine is almost 4:1, invoking OLIGOGENICITY or perhaps the effect of a single recessive allele. In most other cases, the MZ:DZ ratios converge to 2:1, which is consistent with alleles of individual effect, and the genetic heterogeneity model. The relative importance of polygenicity versus heterogeneity has implications for the potential diagnostic use of genetic markers and for strategies to identify gene effects. High within-gene heterogeneity (for example, of the breast cancer 1, early onset (BRCA1) gene in certain cancers) can cause the failure of case-control association analysis using HAPLOTYPES, because different risk alleles will often reside on different haplotypes. By contrast, individual families and isolated populations could be more useful under a model of high genetic heterogeneity. Under a model of polygenicity and strong epistatic effects, some loci might be undetectable except by two-locus analysis, which should be used with trepidation because of the geometric increase in the number of tests carried out, and the consequent loss of power. The seven criteria for substance dependence
• The need for markedly increased amounts of the substance to achieve intoxication or desired effect, or diminished effect with continued use of the same amount (tolerance).
• Withdrawal syndrome or use of the substance to relieve or avoid withdrawal symptoms.
• One or more unsuccessful efforts to cut down or control use.
• Use in larger amounts or over a longer period than intended.
• Important social, occupational or recreational activities are given up or reduced because of substance use.
• A large amount of time is spent in activities that are necessary to obtain, to use or to recover from the effects of the substance.
• Continued use despite knowledge of having persistent or recurrent physical or psychological problems that are caused or exacerbated by the substance.
The four criteria for substance abuse
• Recurrent use resulting in a failure to fulfil the main obligations at work, school or home.
• Recurrent use in physically hazardous situations.
• Recurrent substance-related legal problems.
• Continued use despite persistent or recurrent social or interpersonal problems that are caused or exacerbated by the substance.
For both disorders, symptoms must occur within the same 12-month period. The abuse diagnosis is excluded in patients who have ever been dependent.
COMORBIDITY
The co-occurrence of two or more diseases in an individual or an excess of disease co-occurrence in a population.
PHENOCOPY
Describes the situation in which a phenotype of an environmental origin mimics a phenotype of a genetic origin.
GENOCOPY
Describes the situation in which a phenotype of a genetic origin mimics a phenotype of a different genetic origin.
PENETRANCE
The probability of expressing a phenotype that is determined by a genotype.
LOCUSBASED LINKAGE
The detection of locus-to-locus or locus-to-phenotype genetic linkage. This is generally accomplished by detecting a lack of meiotic recombination in families in which alleles at one locus are observed to be in coupling (co-transmitted) or repulsion (not co-transmitted) with alleles at a second locus.
Shared and unshared inheritance. The abuse of drugs is frequently associated with the abuse of other drugs 16 . COMORBIDITY between disorders poses the question of shared causation, which is being answered by genetic transmission and linkage studies and studies of the neurobiological basis of addiction. The genetic studies address the extent to which variation in liability of different diseases is shared or unshared. Briefly, this is done by evaluating whether the disease status of a proband is predictive of the risk of developing a different disease in a relative; for example, a twin. Genetic studies that cross-compare risks for two phenotypes in twins and other relative pairs indicate that some risk factors are substance-specific whereas others are shared between different substances (reviewed by Goldman and Bergen 17 ). Alcoholism and nicotine addiction, for example, are both comorbid and cross-transmitted. Approximately 85% of alcoholics smoke. Some 50% of the genetic liability to nicotine dependence is shared with alcoholism, and 15% of the genetic liability to alcoholism is shared with nicotine dependence 18 . These findings are guiding investigators to study genes involved in neurobiologies that are common to diverse addictive agents; for example, the nicotinic receptor subunit genes that are gatekeepers for nicotine action 19 are also modulated by ethanol 20 . Although such cross-transmission studies have a unique ability to detect the effects of common aetiology, they have important limitations. For example, the within-family shared environment might be more important in influencing which drug is used compared with whether a person becomes addicted to the drug. It is also more difficult to detect crosstransmission of the rarer addictions than it is for common addictions such as alcoholism and nicotine dependence 2, 8 . These observations could help to explain the high substance-specific heritability (0.70) for heroin among Vietnam veterans 21 compared with the Virginia registry, where rates of exposure were lower and heroin-specific heritability was not detected 22 .
Gene identification: positional cloning
Because addictions are common, it is possible to assemble large family and population datasets. The US National Institute on Drug Abuse (NIDA) Genetics Consortium is assembling datasets that consist of DNA, clinical diagnoses and other information relevant to drug addictions, and will be made available in 2006. Part of the US National Institute on Alcohol Abuse and Alcoholism (NIAAA) Collaborative Study on the Genetics of Alcoholism (COGA) dataset is available. Because addictions are common, the relative risk (λ, which is the ratio of familial risk to population risk) is not high for any of them and large datasets are therefore required. PHENOCOPIES and GENOCOPIES, as well as non-PENETRANCE, are important problems for these diseases, and the role of protective alleles is significant. Therefore, it is generally as informative to evaluate phenotypically unaffected and discordant relative pairs as it is to study affected relative pairs. The high population prevalences have also made it relatively easier to carry out linkage analysis in environmentally and genetically homogeneous population isolates such as southwestern Native Americans 23 and Finns 24 . Such studies can be extended to larger population-based datasets, such as the Icelandic population 25 , which has proved powerful for the genetic analysis of complex diseases 26 . Whole-genome linkage analysis using moderately sized marker panels and LOCUSBASED LINKAGE on families that are derived from the cosmopolitan population of the United States and from population isolates has yielded replicated linkages to chromosomal regions 27 , even when these studies have used heterogeneous definitions such as alcohol dependence 23, 28 , antisocial alcoholism 24 or alcoholism with depressive syndrome 29 . Whole-genome scans using the allele-based LINKAGE DISEQUILIBRIUM approach have been carried out for addictions 30 using a relatively small panel of SNP markers. These studies will be further facilitated by the large arrays of markers that are available through the International HapMap Project. Around 1,000,000 SNPs and their linkage disequilibrium relationships and allele frequencies in four populations are recorded in the HapMap database. This project allows the selection of informative panels of marker loci, as well as known and potential functional loci, for almost any gene. Various methods for large-scale genotyping, including array methods, allow markerintensive gene, region-based and whole-genome linkage disequilibrium studies to be carried out. In this regard, NIDA recently announced its sponsorship of a whole-genome linkage disequilibrium scan for addictions. S ti m u la n ts (2 ,2 1 2 ) C a n n a b is (7 , The excess and complementary deficit of combinations of alleles at two different loci, which is based on rarity of meiotic recombination between loci on the same chromosome.
BENZODIAZEPINE DRUGS
Structurally similar selective GABA A receptor agonists that have potent anxiolytic, sedative, central muscle relaxant and anti-epileptic properties.
QUANTITATIVE TRAIT LOCUS
A genetic locus that is identified through the statistical analysis of complex traits (such as body weight). These traits are typically affected by more than one gene and by the environment.
PHARMACODYNAMIC
Relating to the response of cells and tissues to drugs.
PHARMACOKINETIC
Relating to drug absorption, distribution or metabolism.
A non-exhaustive list of convergences across studies includes the telomere of chromosome 11p, which contains the dopamine receptor D4 (DRD4) gene and several other neurogenetic candidate genes. Another region, on chromosome 4q, contains the alcohol dehydrogenase (ADH) gene cluster, whereas a chromosome 4p region near the centromere contains a γ-aminobutyric acid receptor A (GABA A ) gene cluster.
The GABA receptor. GABA is the principal inhibitory neurotransmitter in the brain and GABA A receptormediated chloride currents into neurons are facilitated by alcohol and by BENZODIAZEPINE DRUGS, with which alcohol shows cross-tolerance. A series of mouse ethanol-related behaviours, including preference, withdrawal severity and sedation sensitivity, map to four QUANTITATIVE TRAIT LOCUS (QTL) regions at which GABA A receptor-gene complexes are located 31 . These gene complexes apparently originated from ancient duplications of chromosomes or chromosomal regions, because the order and orientation of subunit gene types are conserved. In the rat, the GABA A α6 subunit gene Arg100Gln missense variant is associated with variation in ethanol and benzodiazepine sensitivity 32 . A human variant of GABA A α6 (Pro385Ser), which is located in the chromosome 5 cluster, is also linked to sensitivity to alcohol 33, 34 and benzodiazepine 35 in relatively small datasets. Low alcohol response or sensitivity is a heritable intermediate phenotype that is predictive of increased alcohol preference in rodents 36 and alcoholism in humans 37 . Variation in human alcohol response and mouse alcohol sensitivity is mainly PHARMACODYNAMIC in origin, rather than metabolic (PHARMACOKINETIC), pointing to potential differences in receptors or signalling molecules that might function as gatekeepers. In humans, both the chromosome 4 REFS 23,38 and chromosome 5 REF. 39 clusters are implicated. Linkage disequilibrium mapping has refined the localization to the GABA A α6 region 39 on chromosome 5 and the GABA A α2 gene region 38 on chromosome 4 (FIG. 5) .
Alcohol dehydrogenase genes. The two outstanding examples of verified human 'addiction genes' encode for enzymes that catalyse consecutive steps in alcohol metabolism: alcohol dehydrogenase IB (ADH1B) and aldehyde dehydrogenase 2 (ALDH2). ADH metabolizes ethanol to acetaldehyde, a toxic intermediate, which is in turn converted to acetate by ALDH. The most important functional loci at these genes are His47Arg in the ADH1B gene and Glu487Lys in the ALDH2 gene. Either higher activity of ADH1B (conferred by the His47 allele) or lower activity of ALDH2 (conferred by the Lys487 allele) leads to accumulation of acetaldehyde following an alcohol load. Acetaldehyde accumulation causes the aversive flushing reaction that discourages further alcohol intake. The genotype-associated flushing that is attributable to the higher activity codominant His47 allele and the lower activity dominant Lys487 allele is equivalent to the effects of disulfiram (a drug that is used to prevent relapse), and to certain antiprotozoal drugs, such as metronidazole, that inhibit ALDH. In several eastern Asian countries, such as Japan, where both His47 and Lys487 are highly abundant, most of the population carries a heterozygous or homozygous genotype that is protective against alcoholism. The protective effect seems to vary across environments 40 and the effects of genotypes are additive 41 . Each of these protective alleles apparently represents a single ancient mutation [42] [43] [44] [45] , based on the highly diverged haplotypes on which they reside, and there is some haplotype-based evidence for maintenance by selection 42 . It is improbable that these gene variants have evolved to protect against alcoholism. It is more plausible that these common gene variants might have conferred some other effect on fitness, such as protection against severe infectious diseases by protozoans that are sensitive to inhibition of alcohol metabolism, either because of their localization in the gut or because of their lack of intrinsic aldehyde dehydrogenase 46 . Figure 2 | Heritability of addictive disorders. a | The heritability (weighted mean and range) of 10 addictive disorders. These include hallucinogens, stimulants, cannabis, sedatives, gambling, smoking persistence, alcohol dependence, caffeine consumption or heavy use, cocaine dependence or abuse, and opiates. b | Weighted heritability (h 2 ) is plotted against the approximate ranking for relative risk of addiction. Relative risk of addiction is expressed on a five-point scale 14 , one indicates the lowest risk and five denotes the highest risk. In parts a and b, h 2 means were calculated using data from the national surveys of adult twins listed in Our understanding of the neurobiological basis of addiction has evolved mainly from studies in animal models BOX 3. The potential uses of animal models are almost limitless owing to the ability to directly access addiction neurobiology and the new and emerging tools to selectively express and downregulate genes in different regions of the brain. As genetic variants that are orthologous to human polymorphisms are discovered, sequencing of mouse, rat and non-human primate genomes is allowing these species to be better exploited.
Progress through intermediate phenotypes
The neurobiological processes that are involved in addiction, including reward, executive cognitive function and stress or anxiety, substantially overlap with those that underlie other psychiatric disorders, leading to the expectation that shared genetic factors are involved. Therefore, it is crucial to determine whether common disease origins determine the excess aggregation of these disorders observed in populations and in families 2, 16, 47, 48 . Such aggregation can be due to the natural course of one disease increasing the risk of developing a second disease or because individuals who are chronic, treatment resistant or psychosocially impaired are more likely to be ascertained 49 . Several loci that alter intermediate phenotypes that are important in shared risk have been found (see below). Intermediate phenotypes that reflect substance-specific neurobiology have been identified -for example, variation in alcohol-induced sedation and euphoria -and are also being used to identify genes that might be substance-specific in their action 34 . Impulsivity and externalizing behaviours. Behavioural control is fundamental for the ability to inhibit the immediate pursuit of pleasurable stimuli and for the development of structured patterns of behaviour that produce long-term rewards. In children, deficits in the development of behavioural control lead to various problems, including substance use 50, 51 . In the Virginia Twin cohort, a common factor encompassing externalizing disorders such as antisocial personality disorder (ASPD) and conduct disorder (CD) accounted for 71% of the genetic liability to alcoholism and 67% of the inheritance of vulnerability to illicit drug abuse or dependence 5 . Data from other twin studies, including a large community sample 52 and a small sample of MZ twins that were reared apart 53 , also revealed the connection between ASPD, CD and alcoholism. In a seminal adoption study, antisocial personality and alcoholism were observed to be cross-inherited 54 . The temporal sequence is consistent with the hypothesis that antisocial behaviours and CD are causal factors for alcoholism and other substance dependencies, because CD usually occurs before alcohol dependence. However, alcohol and other drugs are disinhibiting, leading to antisocial behaviours 55 . In adolescence, the likelihood of alcoholism and drug abuse is diminished by 4-5% for each year that onset of drug use is delayed 56 . Several genes that influence impulsivity and externalization have been found. Polymorphisms in both the DRD4 gene and the dopamine transporter SLC6A3 (solute carrier family 6, member 3) have been linked to attention deficit hyperactivity disorder (ADHD) and CD, with linkage to DRD4 long-repeat alleles being more replicable 57 . Monoamine oxidase A (MAOA) metabolizes dopamine and a rare stop-codon variant of this gene was linked to impulsive behaviour among males in a Dutch family 58 . An abundant MAOA variable number tandem repeat locus is linked to antisocial behaviour in children, in an environment-specific fashion 59 . Serotonin is the neurotransmitter that is most consistently implicated in aggression and impulsivity by neurochemical and neurobehavioural studies in humans and other species 55 . The 5-hydroxytryptamine (serotonin) receptor 1B (HTR1B) gene is located at the site of several mouse alcohol QTLs on chromosome 9, and mice in which this gene has been knocked out were more aggressive and had a preference for alcohol 60 . HTR1B was linked to 'antisocial alcoholism' in a Finnish family sample that was ascertained through criminal alcoholic probands, and in a southwestern Native American community sample 24 . However, replication of the association of HTR1B with impulsivity or aggression has been variable 61, 62 and no functional locus polymorphism is known.
Intermediate phenotypes in impulsivity and externalization have been linked to certain gene regions, and to specific loci. Disturbed attention processes, as assessed by electrophysiological responses to unexpected stimuli, are more common in drug-naive offspring of alcoholics. The use of this phenotype in a whole-genome linkage scan led to the identification of several linkage regions 63 . The chromosome 11p telomere region has been linked to addictions 36 . DRD4 lies on chromosome 11p, and a 16 amino-acid repeat polymorphism in DRD4 has variably been associated with novelty seeking 64, 65 .
The anxiety or dysphoria domain. In the NESARC national epidemiologic survey, all mood and anxiety disorders were comorbid with alcohol and druguse disorders (odds range from 1.6 to 13.9), the strongest correlation being between MANIA and PANIC DISORDER, and AGORAPHOBIA 2 . The magnitude of anxiety and addiction comorbidity is greater in women 48 . Large twin studies 5, 66 provide only weak support for a shared genetic predisposition to substance-use disorders and the mood and anxiety disorders. In a study on females, more than three-quarters of the genetic liability to alcoholism was not shared with major depression, anxiety disorders and BULIMIA 66 . In both men and women, alcoholism and other drug disorders are genetically largely independent from major depression, generalized anxiety and phobic disorders 5 . However, fundamental to the process of addiction is a drug exposure-induced shift to a long-lasting ALLOSTATIC state such that many drug-free addicts show persistent affective disturbances and are vulnerable to craving. This means that they are liable to rapid relapse when triggered by stressful life events or re-exposure to the drug. When re-administered, the drug might elevate mood, but not to the level experienced before addiction 67 . Studies on drug-exposed animals indicate that long-lasting physiological changes take place that are associated with changes in the expression of stress-related genes 68, 69 . It is likely that individuals are predisposed to addiction, based on diminished stress resiliency 69 . Indeed, acute and early-life stress exposures have the effect of increasing the risk of addictions and other psychiatric diseases 70 and of increasing the intake of alcohol and drugs in animal models 71 .
Genes and neurobiologies
Vulnerabilities to substance use diverge diametrically between individuals; this fact provides an opportunity and a challenge for gene mapping. The catechol-Omethyltransferase (COMT) gene provides a powerful example. COMT is an enzyme that metabolizes CATECHOLAMINES, terminating the action of these neurotransmitters in the synapse, particularly in regions of the brain where levels of the relevant monoamine transporters are low. A common polymorphism that exerts an effect on COMT function is Val158Met. The Val158 allele is approximately three times more thermostable than Met158 at normal body temperature, and has 40% higher activity 72 . Furthermore, Val158 and Met158 are found on differentially expressed haplotype backgrounds 73 of ancient origin, as indicated by their opposite (yin-yang) allelic configurations (a 5-locus haplotype pattern of 1122Val versus 2211Met) that are both abundant in populations worldwide 74 . The haplotype analyses predict variation in COMT expression, and it is likely that COMT linkage studies will incorporate haplotype information to capture more details on the functional genetic variation of this gene. For example, linkage of a Val158-containing haplotype to schizophrenia was more robust than the Val158 allele itself 75 , and haplotype analysis was also used in a replication study of linkage of COMT to pain threshold 76 . The higher activity Val158 allele is predicted to reduce dopamine levels in the frontal cortex because levels of the dopamine transporter are low in this region. Consistent with the role of dopamine in the tuning of frontal cortical function, the Val158 allele and Val158 haplotypes have replicably been linked to frontal lobe function, as assessed by measures such as the WISCONSIN CARDSORT TEST and the NBACK TEST [77] [78] [79] , and by the metabolic activity of the frontal cortex during a WORKINGMEMORY task 77 . In certain populations, including polysubstance abusers that were ascertained in Baltimore, USA 80 , the Val158 allele is associated with vulnerability to addiction through impulsivity or dyscontrol. By contrast, in populations of addicts in whom anxiety is a more salient predisposing cause -for example, in late-onset alcoholics 81 and social drinkers 82 -the Met158 allele is more common. The counterbalancing disadvantage (in fitness terms) of the Met158 allele seems to be the enhanced vulnerability of Met158 genotypes to stress and anxiety. Met158 homozygous women in two different populations were more anxious 83 . This balance of advantages in stress resiliency (Val158 allele) versus Figure 4 | Weighted means of monozygotic and dizygotic tetrachoric correlation ratios for 10 addictive disorders. Weighted means of monozygotic to dizygotic ratios were calculated using monozygotic and dizygotic tetrachoric correlations that were estimated from the national surveys of adult twins listed in cognitive function (Met158 allele) forms the basis for the WARRIOR/WORRIER MODEL. This model invokes frequency-dependent selection or balancing selection to conserve both ancient COMT functional alleles across human populations. The warrior haplotype (Val158) leads to better stress resiliency, but also to modest diminution of executive cognitive performance under most conditions. On the other hand, following a pain or stress challenge, the worrier (Met158) allele dosage predicted a progressively lower pain threshold, stronger affective response to pain and inability of the endogenous brain opioid system to become activated following pain 84 . As already mentioned, linkage of Met haplotypes to a lower threshold to experimentally administered painful stimuli was recently replicated in a large cohort of women 76 . Linkage studies of the serotonin transporter gene underline the power of neuroimaging studies and the usefulness of approaches that consider the interaction of environmental and gene effects. Two main alleles of the serotonin transporter polymorphism (HTTLPR) that lie in the promoter of this gene have either 14 (short (S)) or 16 (long (L)) copies of a 22-bp imperfect repeat 85 . The lower transcribing S allele contributes significantly to risk for alcohol dependence, with the greatest effect observed among individuals with more severe alcohol dependence, antisocial behaviour or suicide attempt 86 . However, this locus only has a modest effect on complex behaviour. The S allele has been linked to anxiety, but in a meta-analysis of 23 association studies, each copy of the S allele contributed only a 0.106 standard deviation increment in anxiety that was measured on personality scales 87 . Furthermore, without objectively discarding certain studies there was no significant effect overall 87 . The role of the serotonin transporter in behaviour has been clarified by studies showing that the effect of the S allele in dysphoria and drug consumption might be dependent on exposure to stress 71, 88 . The effects of this locus are clearest at the neurobiological level. The polymorphism alters transporter expression in the brain 89, 90 and in the AMYGDALA, and changes the metabolic response to emotional stimuli 91 and the volume of the amygdala 92 . Recently, the additive effects of HTTLPR alleles and COMT Val158Met allele were observed in the metabolic response of the amygdala to emotional stimuli 93 . A further functional allele was also discovered at the HTTLPR locus (an A to G substitution in the first of the two extra repeats defining the L allele) 94 , which accounts for even more variation in serotonin transporter expression, and improves the ability to predict both complex behaviours and intermediate phenotypes 95 .
From genotype to medical management
The treatment and prevention of addictions are only partially successful. Prevention strategies could focus on children and adults who are vulnerable due to variations in particular neurobiological domains, for example, behavioural dyscontrol versus stress or anxiety. It is still unclear whether such targeting of prevention would be essential or even appropriate. The high rates of addictions and the economics of the problem make it worthwhile to apply many prevention strategies across entire population cohorts without identifying particular vulnerability alleles. However, it would be important to know the efficacy (or lack of effect) of untargeted prevention strategies on individuals with particular vulnerabilities.
Individualization of therapy and the identification of new therapeutic targets are required for the large number of individuals who are already ill, and for the newly incident cases each year. One-year relapse rates for alcoholism and cocaine range from 20 to 60%, depending on the clinical study 96, 97 . Medications for treatment of addictions include AGONISTS (methadone), ANTAGONISTS (naltrexone), anticraving medications and drugs that block the metabolism 98 . Except for the management of the acute phase, addictions remain largely under-treated diseases. Although addictions are chronic and relapsing or remitting, medical management has focused on the acute phase (intoxication and withdrawal) because treatment occurs within a socio-medical matrix in which long-term benefits of prevention and follow-up care are not encouraged by adequate reimbursement 98 . This is despite the efficacy of treatment, which is comparable to that of treatment for other chronic disorders such as diabetes and asthma 98 . For such illnesses, incremental improvements in management that are applied conscientiously have extended life expectancies from less than 20 years to more than 50 years. Improvements in the targeting of addiction treatment and availability of new treatment methods (including new approaches to cognitive and behavioural therapy) could also drive changes in the clinical management of these diseases, leading to a more multidimensional level of care. The clinical subclassifications of addictive disorders are a first systematic effort to create more homogeneous categories to individualize treatment and prevention, and to identify new therapeutic targets. It is precisely at this point that progress has stalled. Although some drugs (for example, naltrexone and acamprosate) have efficacy for the treatment of heterogeneous populations of alcoholics, others (for example, ondansetron and selective serotonin reuptake inhibitors) seem to be differentially effective in subgroups [99] [100] [101] . However, although efforts to clinically subclassify addictions are likely to continue, it is improbable that future meta-groupings of addictions and other psychiatric diseases will advance until neurobiological indicators, including genotypes, are integrated.
Conclusions
Liability to addictions is widespread, but individuals with addicted first-degree relatives are at greater risk. The correlation between the heritability of different addictions and the relatively simple estimates of addiction liability for particular agents indicates that a large component of what is inherited is interindividual variation in the fundamental neurobiological basis of addiction. Advances in the neurobiology of addiction have led to the identification of some underlying genes and have allowed the actions of certain risk loci to be understood. Genetic loci that have defined roles in addictions include substance-specific genes, such as the alcohol metabolic genes, and loci, such as the serotonin transporter and COMT, that alter liability to different addictions and other psychiatric illnesses. Evidence from twin studies indicates that further loci in both addiction substance-specific and addiction substance-nonspecific categories will be discovered. The twin concordance ratio data predict that many of the addiction loci will have an individual effect whenever the functional allele is actually found in a person. This information helps us to postulate that genetic markers with significant predictive value will be discovered and serve as guides to new molecular mechanisms and targets for medicine.
Large datasets and new tools in genetics and molecular neurobiology have facilitated various genetic approaches in humans and other species. These approaches have allowed the detection of gene effects on the clinical phenotypes of addictions that are small on a population basis and that, because of causal heterogeneity, are sometimes inconsistent across different types of addicted patient. Larger and apparently more consistent gene effects are being observed at the levels of neurobiology and of intermediate phenotypes, and owing to the improved understanding of the influence of environmental exposures, particularly stress. Indeed, identifying gene-environment interactions is a crucial issue in the study of addictions, which by definition depend on exposure to an addictive agent and are strongly modulated by other environmental factors. The story of genes in addictions and other complex behavioural 
Studies in rodents have identified both neuroanatomical circuits
112 (such as limbic reward and emotionality circuits) and cellular molecular networks that are crucial in addiction 113, 114 . Several of the genes that are central to drug response and neuroadaptation have already been tested as leading candidates in genetic studies in humans. So far, the brain-derived neurotrophic factor (BDNF) 115 , the 5-hydroxytryptamine (serotonin) receptor 1B (HTR1B) 24 , the γ-aminobutyric acid receptor A (GABA A ) receptor 38 
, neuropeptide Y (NPY)

116
, and the dopamine D2 receptor (DRD2)
117 genes have been implicated in animal studies and evaluated in humans, with promising results. However, most of the strong candidate genes to emerge from animal neurobiological studies of addiction have yet to be evaluated for sequence variation and linkage to human addictive behaviour. These include deltaFosB, and the genes that encode the proline-cysteine transporter, the cyclic-AMP-response element binding protein (CREB), and various glutamate receptors 113, 114 . Animal models allow genes to be associated with neurobiological phenotypes that are not accessible in humans, and with various addiction-related behaviours that are studied under highly controlled conditions. In rodents, genes that are implicated by QTL studies include the µ-opioid receptor 1 (OPRM1) in morphine preference 118, 119 , the multiple PDZ-binding domain protein (MPDZ) in acute pentobarbital and ethanol withdrawal 120 , NPY in ethanol preference 121 , glutamic acid decarboxylase (GAD1), a GABA biosynthetic enzyme, in ethanol-induced locomotion 122 , and DRD2 and HTR1B in ethanol preference 31 . The functional allele has not been verified in any of these cases, but in other examples, effects of alleles, including artificial gene knockouts, are directly known. Cheapdate, a mutation that leads to enhanced sensitivity to ethanol in Drosophila melanogaster, is an allele of the memory mutant Amnesiac and results in diminished activation of the cAMP pathway 123 . In primates, a serotonin transporter promoter locus that is orthologous to a functional polymorphism in the promoter of a human serotonin transporter alters ethanol preference, and this effect can be modified by stress in early life 71 . More than 100 mouse gene knockouts and transgenics alter addiction-related behaviours, reflecting the diversity of pathways that can lead to addiction, and the potential for heterogeneity or polygenicity discussed earlier. OPRM1 mouse knockouts are characterized by reduced opioid-mediated analgesia, reward and physical dependence 124 
.
The knockout for the nicotinic acetylcholine receptor β2 gene blocks nicotine self-administration, reflecting the gatekeeper role of the nicotinic receptor in influencing the self-administration of this drug 125 . Knockouts in signalling genes such as protein kinase C (PKC) 126 or genes that modulate stress response, such as NPY
127
, could be predicted to influence diverse addictive behaviours. diseases seems to be one of incremental progress as the functional significance of sequence variations is discovered and then related both to intermediate phenotypes and to the complex diseases that are emergent from an intermediate neurobiology.
The high population prevalences of addictions and the relative crudity and ineffectiveness of addiction treatment and management constitute a public-health crisis. Through intensive clinical management and the application of new strategies, the outcomes of other chronic medical diseases such as cystic fibrosis 102 and juvenile-onset diabetes 103 have been markedly improved. There is no indication that such comprehensive approaches are on the verge of being developed and applied to the addictions without significant breakthroughs in genetics and neurobiology. It is a sobering reality that genetic findings have so far not led to the creation or targeting of addiction treatment or prevention. Future research is likely to integrate genetic variation ever more closely, with effects on intermediate neurobiological processes such as reward, behavioural control and anxiety response that are now understood to underlie addiction vulnerability and recovery. Such studies will frequently be fine-grained and take advantage of powerful methods that capture neurobiology, including neuroimaging, and direct interventional studies in animals that are not feasible, or ethical, in humans. Future research must also find a role for genotypes, either as guides to new therapeutic targets or as predictors for treatment and prevention, in natural populations of patients and individuals at risk where the efficacy of new tools can objectively be defined and integrated into multidimensional management.
